biOasis Technologies Inc
XTSX:BTI
Relative Value
The Relative Value of one BTI stock under the Base Case scenario is 0.02 CAD. Compared to the current market price of 0.01 CAD, biOasis Technologies Inc is Undervalued by 55%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
BTI Competitors Multiples
biOasis Technologies Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CA |
biOasis Technologies Inc
XTSX:BTI
|
397.1k CAD | 1.5 | -0.1 | -0.3 | -0.3 | ||
US |
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 5.9 | 24.8 | 17.9 | 26.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 8 | 26.5 | 17.8 | 19.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.9 | 166.8 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 7 | -10.1 | -11 | -9.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 3.3 | 27.1 | 13.9 | 17.4 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |